AFT.NZ Stock — Price, Charts & Analysis

AFT Pharmaceuticals Limited (AFT.NZ) has a trailing P/E of 31.57x and a forward P/E of 18.68x. This places AFT.NZ in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

AFT.NZ trades with 31.57x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether AFT.NZ looks overvalued or undervalued.

AFT.NZ's P/E of 31.57x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

AFT.NZ's trailing EPS is NZ$0.14 and forward EPS is NZ$0.24. Reported earnings growth is -16.50%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit AFT Pharmaceuticals Limited generated for each share. AFT.NZ's trailing EPS is NZ$0.14, and investors usually prefer EPS that is positive and growing over time.

AFT Pharmaceuticals Limited has a market cap of NZ$463.51M, making AFT.NZ a small-cap stock based on the current market value shown on Worldtickers.

AFT.NZ's latest stock price on Worldtickers is NZ$4.42. The latest move is NZ$0.02 or 0.45%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

AFT.NZ's quote includes a latest price of NZ$4.42. The market open is NZ$4.40. Previous close is NZ$4.40. The intraday range is NZ$4.40 to NZ$4.45.

AFT.NZ is up in the latest quote, with a move of NZ$0.02 or 0.45%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

AFT.NZ generated NZ$254.70M in trailing revenue. Revenue growth is 15.20%, which helps show whether demand is expanding or slowing.

AFT.NZ's revenue growth is 15.20%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, AFT.NZ shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is NZ$14.73M.

Gross margin is 43.40%. Margins show how efficiently AFT Pharmaceuticals Limited turns revenue into profit.

AFT Pharmaceuticals Limited carries NZ$54.11M and holds NZ$10.24M in cash.

AFT.NZ holds NZ$10.24M on its balance sheet.

AFT.NZ's book value per share is NZ$1.05.

Yes, AFT Pharmaceuticals Limited pays a dividend of NZ$0.03 per share annually. The dividend yield is 57.00%. The payout ratio is 12.86%.

AFT.NZ's dividend yield is 57.00%. Its payout ratio is 12.86%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for AFT.NZ. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through AFT Pharmaceuticals Limited's investor relations materials.

Institutions hold 1.09% of AFT.NZ shares. Insiders hold 77.64% of shares. Ownership mix helps investors understand how much of AFT Pharmaceuticals Limited is held by professional investors and company insiders.

AFT.NZ has 104.87M shares outstanding. Float shares are 30.43M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for AFT.NZ, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for AFT.NZ is NZ$0.24. Earnings growth is -16.50%. Revenue growth is 15.20%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

AFT.NZ's trailing EPS is NZ$0.14. Forward EPS is NZ$0.24. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

AFT.NZ is in the Healthcare sector. Its earnings multiple is 31.57x. Its latest displayed growth metric is 15.20%. Compare these figures with sector peers before deciding whether AFT Pharmaceuticals Limited is stronger or weaker than average.

AFT.NZ trades at NZ$4.42. The stock trades at 31.57x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of AFT Pharmaceuticals Limited's fundamentals.

AFT.NZ risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.47, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

AFT.NZ should be compared with companies in Drug Manufacturers - Specialty & Generic. Its earnings multiple is 31.57x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

AFT Pharmaceuticals Limited (AFT.NZ) operates in Healthcare, specifically Drug Manufacturers - Specialty & Generic. AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers proprietary and in-licensed products, including patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, natural health, pain management, skin care, sleeping aids, supplements, and other products. It has a research and development collaboration wi

AFT.NZ trades on NZSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

AFT.NZ stock is priced in NZD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

AFT Pharmaceuticals Limited's official website listed on Worldtickers is www.aftpharm.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

AFT Pharmaceuticals Limited employs about 126 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

AFT Pharmaceuticals Limited is headquartered in Auckland, New Zealand. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

AFT.NZ is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

AFT.NZ has traded between NZ$2.56 and NZ$4.85 over the past 52 weeks. At NZ$4.42, it is 8.87% below the high and 72.66% above the low. The 52-week range helps gauge long-term price momentum.

AFT.NZ is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is NZ$4.12 and its 200-day moving average is NZ$3.70.

AFT.NZ's RSI is 53.49. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

AFT.NZ's latest RSI reading is 53.49, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for AFT.NZ is near NZ$4.00. Key resistance is near NZ$4.85. Breaks above resistance or below support can change the short-term technical setup.

AFT.NZ's nearest reported support level is NZ$4.00. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

AFT.NZ's nearest reported resistance level is NZ$4.85. A breakout above resistance can improve momentum, especially when volume confirms the move.

AFT.NZ trades about 35.89K shares daily on average. The latest displayed volume is 8K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

AFT.NZ's MACD is -0.05, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

AFT.NZ is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 53.49 (neutral). MACD is bearish. Nearest support is around NZ$4.00. Resistance is around NZ$4.85. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is NZ$4.56 (-3.05% from price). MA50 is NZ$4.12 (7.31% from price). MA200 is NZ$3.70 (19.60% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. AFT.NZ's MA20 is NZ$4.56. MA50 is NZ$4.12. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

AFT.NZ's pivot is near NZ$4.40. Support is near NZ$4.00. Resistance is near NZ$4.85. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for AFT.NZ is near NZ$4.00. These levels help define risk and possible follow-through zones after a breakout or breakdown.

AFT.NZ's Bollinger range is roughly NZ$4.17 to NZ$4.95. Band width is near 17.13%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

AFT.NZ's ATR-based typical daily range is about 1.92%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 8K shares. Average volume is about 35.89K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

AFT.NZ's all-time high shown on Worldtickers is NZ$5.65. Its all-time low is NZ$1.70. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

AFT.NZ has a beta of 0.47, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.